Product Description
| Brand |
Snibe |
| Sample Type |
Serum |
| Pack Size |
100T |
| CAT No. |
130201013M |
| Application |
Cancer Marker |
The kit has been designed for the quantitative determination of CYFRA21-1 in human serum. The method can be used for samples over the range of 1.0-1,000 ng/ml. The test has to be performed on the Fully-auto chemiluminescence immunoassay (CLIA) analyzer MAGLUMI (Including Maglumi 600,Maglumi 1000,Maglumi 1000 Plus, Maglumi 2000,Maglumi 2000 Plus,Maglumi 3000 and Maglumi 4000).
Advanced Chemiluminescent Immunoassay TechnologyLeveraging sandwich Chemiluminescent Immunoassay (CLIA) methodology, the MAGLUMI CYFRA 21-1 kit offers clinicians reliable and precise detection of CYFRA 21-1, contributing significantly to the diagnosis and monitoring of lung cancer. The technology enables real-time, automated operation and high-throughput capabilities.
Comprehensive and Easy-to-Use KitThe kit includes all needed calibrators and controls, eliminates the need for additional reagents, and requires only a small sample volume. The user-friendly format is specifically crafted for laboratory professionals, ensuring consistent and reproducible results with minimal manual intervention.
Versatile and Efficient for Laboratory SettingsOptimized for use with MAGLUMI series analyzers, the kit facilitates fast turnaround-delivering results in about 30 minutes. Its quantitative range covers 0.1 ng/mL to 100 ng/mL, making it suitable for routine and advanced clinical applications in detecting and monitoring lung tumor markers.
FAQ's of Snibe MAGLUMI CYFRA 21-1 (CLIA):
Q: How does the Snibe MAGLUMI CYFRA 21-1 (CLIA) test work?
A: This test uses a sandwich Chemiluminescent Immunoassay (CLIA) principle to quantitatively detect CYFRA 21-1 in human serum or plasma. The MAGLUMI analyzer automatically processes samples and measures chemiluminescent signals generated by antigen-antibody binding.
Q: What type of samples can be used with this reagent kit?
A: The kit is compatible with either human serum or plasma samples, requiring just 50 L per test. This flexibility allows laboratories to utilize readily available sample types.
Q: When should CYFRA 21-1 testing be performed?
A: CYFRA 21-1 testing is typically used to aid in diagnosing and monitoring lung cancer, particularly non-small cell lung cancer. Testing may be performed during patient assessment, ongoing monitoring, or when clinical suspicion arises.
Q: Where can the Snibe MAGLUMI CYFRA 21-1 (CLIA) kit be used?
A: This diagnostic reagent kit is intended for laboratory use only. It must be used with MAGLUMI series automated immunoassay analyzers, typically found in clinical diagnostic or research laboratories.
Q: What is the process and turnaround time for testing with this kit?
A: Once loaded onto the MAGLUMI analyzer, the automated process delivers quantitative CYFRA 21-1 results in approximately 30 minutes, supporting high-throughput testing protocols.
Q: What are the main benefits of using the MAGLUMI CYFRA 21-1 reagent kit?
A: Key advantages include high sensitivity and specificity, automation for rapid workflows, comprehensive controls, and a broad measurement range, leading to efficient and accurate tumor marker detection.
Q: How should the reagent kit be stored for optimal performance?
A: Unopened kits should be stored at 2-8C and protected from light. The shelf life is 12 months under proper storage conditions.